Demetris Anthony J, Zeevi Adriana, O'Leary Jacqueline G
aDivision of Transplantation, Department of Pathology, Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania bAnnette C. & Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, Texas, USA.
Curr Opin Organ Transplant. 2015 Jun;20(3):314-24. doi: 10.1097/MOT.0000000000000194.
Liver allograft antibody-mediated rejection (AMR) studies have lagged behind parallel efforts in kidney and heart because of a comparative inherent hepatic resistance to AMR. Three developments, however, have increased interest: first, solid phase antibody testing enabled more precise antibody characterization; second, increased expectations for long-term, morbidity-free survival; and third, immunosuppression minimization trials.
Two overlapping liver allograft AMR phenotypic expressions are beginning to emerge: acute and chronic AMR. Acute AMR usually occurs within the several weeks after transplantation and characterized clinically by donor-specific antibodies (DSA) persistence, allograft dysfunction, thrombocytopenia, and hypocomplementemia. Acute AMR appears histopathologically similar to acute AMR in other organs: diffuse microvascular endothelial cell hypertrophy, C4d deposits, neutrophilic, eosinophilic, and macrophag-mediated microvasculitis/capillaritis, along with liver-specific ductular reaction, centrilobular hepatocyte swelling, and hepatocanalicular cholestasis often combined with T-cell-mediated rejection (TCMR). Chronic AMR is less well defined, but strongly linked to serum class II DSA and associated with late-onset acute TCMR, fibrosis, chronic rejection, and decreased survival. Unlike acute AMR, chronic AMR is a slowly evolving insult with a number of potential manifestations, but most commonly appears as low-grade lymphoplasmacytic portal and perivenular inflammation accompanied by unusual fibrosis patterns and variable microvascular C4d deposition; capillaritis can be more difficult to identify than in acute AMR.
More precise DSA characterization, increasing expectations for long-term survival, and immunosuppression weaning precipitated a re-emergence of liver allograft AMR interest. Pathophysiological similarities exist between heart, kidney, and liver allografts, but liver-specific considerations may prove critical to our ultimate understanding of all solid organ AMR.
由于肝脏对抗体介导的排斥反应(AMR)具有相对内在的抗性,肝脏移植抗体介导的排斥反应研究落后于肾脏和心脏的相关研究。然而,有三个进展增加了人们的兴趣:第一,固相抗体检测能够更精确地表征抗体;第二,对长期无发病存活的期望增加;第三,免疫抑制最小化试验。
两种重叠的肝脏移植AMR表型表达开始出现:急性和慢性AMR。急性AMR通常发生在移植后的几周内,临床特征为供体特异性抗体(DSA)持续存在、移植肝功能障碍、血小板减少和补体减少。急性AMR在组织病理学上与其他器官的急性AMR相似:弥漫性微血管内皮细胞肥大、C4d沉积、中性粒细胞、嗜酸性粒细胞和巨噬细胞介导的微血管炎/毛细血管炎,以及肝脏特异性小胆管反应、小叶中心肝细胞肿胀和肝小管胆汁淤积,常与T细胞介导的排斥反应(TCMR)合并。慢性AMR的定义不太明确,但与血清II类DSA密切相关,并与迟发性急性TCMR、纤维化、慢性排斥反应和存活率降低有关。与急性AMR不同,慢性AMR是一种缓慢发展的损伤,有许多潜在表现,但最常见的表现为低度淋巴浆细胞性门静脉和静脉周围炎症,伴有不寻常的纤维化模式和可变的微血管C4d沉积;毛细血管炎可能比急性AMR更难识别。
更精确的DSA表征、对长期存活的期望增加以及免疫抑制的逐渐减少促使人们重新关注肝脏移植AMR。心脏、肾脏和肝脏移植之间存在病理生理相似性,但肝脏特异性因素可能对我们最终理解所有实体器官AMR至关重要。